Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
about
A 3-year randomized therapeutic trial of nitisinone in alkaptonuriaRecommendations for the management of tyrosinaemia type 1Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).Triketone toxicity: a report on two cases of sulcotrione poisoning.Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
P2860
Q24624747-D989BFAA-62E9-42CD-8D0E-674000459412Q26851571-7DC5D898-26CC-493E-836B-D7117B9C69B6Q34560227-2CF58F63-9DF9-4A80-87AF-467ECB33521DQ34590786-3CAB3494-FE00-468C-9032-D1537954DBBCQ35141048-B74BDA5F-B05F-4C8C-8ED1-D068D7E113E5Q36090590-A27ADE7E-83F8-4B91-9A30-6AF8AE92EADCQ37735158-0442BB25-A853-4B01-B583-E33C15908F8EQ38869592-1FCDB087-BCEE-45FD-A038-170DB8C924D3Q39024172-5A2CA2C4-5FC4-468A-B182-46FB8458C889Q41878517-0C9D59A0-8F0E-453B-9AB6-164FD15F655FQ42339142-0A4B6E0E-92CF-4385-91C0-8E94469816F3Q44529698-61371105-691E-464B-874E-634C94037EB3Q47137137-AD367D99-4C02-49B7-BA82-39589CEA5994Q47753281-3A44C0E6-5634-4E9E-9313-8BC33B5BCAF0Q50850348-0D3D7F35-253E-4985-A23D-88F0310B71F2
P2860
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@ast
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@en
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@nl
type
label
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@ast
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@en
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@nl
prefLabel
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@ast
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@en
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@nl
P2093
P356
P1476
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
@en
P2093
McKiernan PJ
Willshaw HA
P2888
P356
10.1023/A:1024011110116
P577
2003-01-01T00:00:00Z
P6179
1024824590